COMPUGEN LTD (CGEN) research
COMPUGEN LTD- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.49
- As of
COMPUGEN LTD (CGEN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-10.
As of . Source: SEC EDGAR filings for CGEN. Method and limitations.
Share the CGEN intelligence card
See CGEN live in the terminal
Track CGEN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live CGEN terminal, freeActive signals for CGEN
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in CGEN
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +55% to CGEN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +505% to CGEN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +190% to CGEN (2026Q2)
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in CGEN
FREE, NO ACCOUNT
Every signal on CGEN, as it fires
You are seeing 5 of 23 signals recorded on CGEN since 2026-05-16.
The five above all landed on 2026-09-06. The other 18 were recorded on 6 other days. 15 of the 23 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CGEN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP M25722105 · 2026Q2 | $4M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP M25722105 · 2026Q2 | $1.1M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP M25722105 · 2026Q2 | $561K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP M25722105 · 2026Q2 | $222K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP M25722105 · 2026Q2 | $25K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CGEN
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
CGEN against its peers
CGEN's operating margin of 43.1% ranks in the 97th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | CGEN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 72.8M USD | 17.0M USD | 77 | 14 |
| Revenue YoY | 161.1% | n/a | n/a | 2 |
| Gross margin | 87.3% | n/a | n/a | 2 |
| Operating margin | 43.1% | -340.4% | 97 | 15 |
| Net margin | 48.6% | -301.7% | 97 | 15 |
| Return on equity | 34.4% | -49.4% | 97 | 16 |
Peers (19): NAGE, WHWK, BCYC, SLGL, MGNX, ADAG, YDES, LCTX, ACIU, ALEC, AVXL, IVVD, KROS, NGEN, TARA, LYEL, RNAC, ANTX, NWBO. Left out: TNXP (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (CGEN: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CGEN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CGENand get the insider, 13F, options, and confluence read in one view.